Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 5;9(11):3568.
doi: 10.3390/jcm9113568.

Five-Year Trends in Potential Drug Interactions with Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation: An Australian-Wide Study

Woldesellassie M Bezabhe  1 , Luke R Bereznicki  1 , Jan Radford  2 , Barbara C Wimmer  1 , Mohammed S Salahudeen  1 , Ivan Bindoff  1 , Edward Garrahy  2 , Gregory M Peterson  1
Affiliations

Five-Year Trends in Potential Drug Interactions with Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation: An Australian-Wide Study

Woldesellassie M Bezabhe et al. J Clin Med. .

Abstract

Background: Co-prescribing medications that can interact with direct-acting oral anticoagulants (DOACs) may decrease their safety and efficacy. The aim of this study was to examine the co-prescribing of such medications with DOACs using the Australian national general practice dataset, MedicineInsight, over a five-year period.

Methods: We performed five sequential cross-sectional analyses in patients with atrial fibrillation (AF) and a recorded DOAC prescription. Patients were defined as having a drug interaction if they had a recorded prescription of an interacting medication while they had had a recorded prescription of DOAC in the previous six months. The sample size for the cross-sectional analyses ranged from 5333 in 2014 to 19,196 in 2018.

Results: The proportion of patients who had potential drug interactions with a DOAC decreased from 45.9% (95% confidence interval (CI) 44.6%-47.4%) in 2014 to 39.9% (95% CI 39.2%-40.6%) in 2018, p for trend < 0.001. During this period, the most frequent interacting class of medication recorded as having been prescribed with DOACs was selective serotonin/serotonin and norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants, followed by non-steroidal anti-inflammatory drugs (NSAIDs), calcium channel blockers (CCBs) and amiodarone.

Conclusions: Overall, potential drug interactions with DOACs have decreased slightly over the last five years; however, the rate of possible interaction with SSRIs/SNRIs has remained relatively unchanged and warrants awareness-raising amongst prescribers.

Keywords: atrial fibrillation; direct-acting oral anticoagulants; drug–drug interactions; primary care.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Trends in potential drug interactions in patients taking direct-acting oral anticoagulants.
See this image and copyright information in PMC

References

    1. Zulkifly H., Lip G.Y.H., Lane D.A. Epidemiology of atrial fibrillation. Int. J. Clin. Pr. 2018;72:e13070. doi: 10.1111/ijcp.13070. - DOI - PubMed
    1. Staerk L., Wang B., Preis S.R., Larson M.G., Lubitz S.A., Ellinor P.T., McManus D.D., Ko D., Weng L.-C., Lunetta K.L., et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: Cohort study based on longitudinal data from the Framingham Heart Study. BMJ. 2018;361:k1453. doi: 10.1136/bmj.k1453. - DOI - PMC - PubMed
    1. Benjamin E.J., Muntner P., Alonso A., Bittencourt M.S., Callaway C.W., Carson A.P., Chamberlain A.M., Chang A.R., Cheng S., Das S.R., et al. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association. Circulation. 2019;139:e56–e528. doi: 10.1161/CIR.0000000000000659. - DOI - PubMed
    1. Alamneh E., Chalmers L., Bereznicki L.R. Changes in Oral Anticoagulant Prescribing for Stroke Prevention in Patients With Atrial Fibrillation. Am. J. Cardiol. 2017;120:1133–1138. doi: 10.1016/j.amjcard.2017.06.055. - DOI - PubMed
    1. Drug Utilisation Sub-Committee (DUSC) Novel Oral Anticoagulant: Predicted vs. Actual Analysis. Public Release Document: National Prescribing Service. Australian Government, Department of Health; Canberra, Australia: Jun, 2016.

LinkOut - more resources